Renibus Therapeutics, a US-based clinical-stage biopharmaceutical company, announced on Wednesday that it has dosed its first patient in the pivotal Phase three PROTECT trial of RBT-1, the company's first-in-a-new-class preconditioning agent, under investigation to reduce post-operative complications following cardiothoracic surgery.
PROTECT is expected to be carried out at around 35 sites in the United States and Canada. It is a phase three randomised, double blind, placebo-controlled study to assess the impact of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery.
RBT-1 (stannic protoporfin/iron sucrose), a fixed dose combination product, is administered once intravenously over one to two hours, 24-48 hours prior to surgery. It is claimed to be a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. In a completed Phase two study, RBT-1 demonstrated statistically significant positive data in primary and several secondary endpoints, with reduced time in the ICU, reduced patient recovery time and fewer hospital readmissions.
The study, a randomised, double-blind, multi-centre, placebo-controlled trial, is assessing the impact of RBT-1 in around 400 subjects.
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
SFA Therapeutics names new chief operating officer
argenx and Zai Lab win China approval for efgartigimod SC
Scinai Immunotherapeutics reports positive results in psoriasis study
Spine BioPharma, signs agreement with Ensol BioSciences
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323
Q32 Bio added to Russell 3000 Index
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)